Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Neurodegeneration Could Be Countered via Activation of Neural Stem Cells

Neural stem cells (NSCs) are important for the development and regeneration of the nervous system. After the initial development of the brain, neural stem cells typically enter a dormant state, conserving energy and resources. They re-awaken only when the brai

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Neural stem cells (NSCs) are important for the development and regeneration of the nervous system. After the initial development of the brain, neural stem cells typically enter a dormant state, conserving energy and resources. They re-awaken only when the brain needs them, such as after an injury or with physical exercise. However, with age, fewer neural stem cells can be roused from their dormant state, leading to various neurological conditions. Now, an international team of neuroscientists, led by Duke-NUS Medical School, has uncovered that modifying a protein that controls cell growth can reactivate dormant neural stem cells in fruit flies, offering new hope in the fight against neurological diseases.

The research, published in Nature Communications, in an article titled, “SUMOylation of Warts Kinase Promotes Neural Stem Cell Reactivation,” offers exciting potential for advancing the understanding and treatment of neurodegenerative diseases like Alzheimer’s and Parkinson’s diseases.

“A delicate balance between neural stem cell (NSC) quiescence and proliferation is important for adult neurogenesis and homeostasis. Small ubiquitin-related modifier (SUMO)-dependent post-translational modifications cause rapid and reversible changes in protein functions. However, the role of the SUMO pathway during NSC reactivation and brain development is not established. Here, we show that the key components of the SUMO pathway play an important role in NSC reactivation and brain development in Drosophila.”

The team discovered that a specific group of proteins plays an essential role in “waking up” dormant neural stem cells through a process called SUMOylation. In SUMOylation, a small protein named SUMO tags target proteins inside a cell to influence their activity and/or function. These SUMO-tagged proteins, the researchers found, trigger the reactivation of neural stem cells, allowing them to contribute to brain development and repair. Conversely, without SUMO proteins present, the fruit flies produced a microcephaly-like phenotype. This is the first study to pinpoint the SUMO protein family’s exact role in the reactivation of neural stem cells.

“We have demonstrated for the first time that the SUMO protein family plays a pivotal role in neural stem cell reactivation and overall brain development,” said Gao Yang, PhD, a research fellow with Duke-NUS’ Neuroscience and Behavioral Disorders Program and the study’s first author. “Going a step further, we also showed that when these proteins are absent, normal neuronal development is hampered, with fruit flies developing undersized brains characteristic of microcephaly.”

Delving deeper into the effects of SUMOylation, the researchers determined that it regulates a key protein in another well-known pathway, called Hippo. While the Hippo pathway is known to play a crucial role in cellular processes such as cell proliferation, cell death, and organ size, very few regulators of this pathway in the brain are known.

When modified by SUMO, the Hippo pathway’s central protein Warts, which limits cell growth and prevents the reactivation of neural stem cells, becomes less effective. This allows neural stem cells to grow and divide, forming new neurons that contribute to brain function.

“Given that SUMO proteins and the Hippo pathway are highly conserved in humans, our findings aren’t just relevant for fruit flies,” said Wang Hongyan, PhD, professor and acting program director of the Neuroscience and Behavioral Disorders Research Program and senior author of the study. “They’re also important for understanding human biology. Disruptions in the SUMOylation process and Hippo pathway are linked to various illnesses in humans, including cancer and neurodegenerative diseases, like Alzheimer’s and Parkinson’s diseases. Our new insights into the role of SUMOylation in the brain opens exciting new opportunities for interventions that could lead to targeted therapies that harness the body’s own regenerative powers.”

“This discovery advances our understanding of how cells work and are controlled, informing the development of new regenerative therapeutics for neurodegenerative diseases,” added Patrick Tan, MD, PhD, professor and senior vice-dean for research at Duke-NUS. “At the same time, it opens new possibilities for developing treatments for neurological conditions such as microcephaly. As research continues, we move closer to finding effective ways to help people with these disorders and improve their quality of life.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →